It was confirmed that the opinions of the Central Pharmaceutical Affairs Council members were also mixed over the limited use of Janus kinase Inhibitors, which is used as a treatment for inflammatory diseases. The MFDS announced on the 15th that high-risk patients aged 65 or older, high-risk cardiovascular groups, and malignant tumors will be able to use them only when they are insufficient with existing treatments. 65 items of JAK inhibitors (Tofacitinib, Baricitinib, Upacitinib, Abrocitinib, and Filgotinib) were licensed in Korea.

According to the minutes of the Central Pharmaceutical Affairs Council held last month, the committee members gathered opinions on the current status of foreign countries, r